HEALTH RESOURCE UTILIZATION (HRU) AND COSTS FOR METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH FIRST-LINE (1L) SYSTEMIC THERAPY IN THE UNITED STATES

被引：0
|
作者：
Mhatre, S. [1 ]
Lin, S. [1 ]
Surinach, A. [2 ]
Vohra, R. [1 ]
Satram-Hoang, S. [1 ]
Simpson, J. [1 ]
Wallen, H. [1 ]
Ogale, S. [1 ]
Gong, J. [3 ]
Pal, S. K. [3 ]
George, D. J. [4 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Genesis Res LLC, Hoboken, NJ USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA USA
[4] Duke Univ Hosp, Durham, NC USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2332
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN256
引用
收藏
页码：A755 / A755
页数：1
相关论文
共 50 条
  • [41] Time to first-line (1L) therapy discontinuation in metastatic melanoma (MM).
    Luke, Jason J.
    Ghate, Sameer
    Ionescu-Ittu, Raluca
    Ndife, Briana
    Burne, Rebecca
    Laliberte, Francois
    Duh, Mei Sheng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [42] Health Care Resource Use for Modern First-Line Treatments in Metastatic Renal Cell Carcinoma
    Shah, Neil J.
    Shinde, Reshma
    Moore, Kristin J.
    Sainski-Nguyen, Amy
    Le, Lisa B.
    Cao, Feng
    Song, Rui
    Singhal, Puneet
    Motzer, Robert J.
    JAMA NETWORK OPEN, 2024, 7 (07)
  • [43] COMPARISON OF HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS RELATED TO PLEURAL EFFUSION (PE) BETWEEN PATIENTS NEWLY DIAGNOSED WITH CHRONIC MYELOID LEUKEMIA (CML) TREATED WITH DASATINIB OR NILOTINIB AS FIRST-LINE THERAPY IN THE UNITED STATES
    Seiter, K.
    Latremouille-Viau, D.
    Guerin, A.
    Ndife, B.
    Habucky, K.
    Joseph, G. J.
    Pivneva, I
    Gagnon-Sanschagrin, P.
    Tang, D. H.
    VALUE IN HEALTH, 2018, 21 : S28 - S28
  • [44] Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma
    David M. Gill
    Andrew W. Hahn
    Peter Hale
    Benjamin L. Maughan
    Current Treatment Options in Oncology, 2018, 19
  • [45] Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma
    Gill, David M.
    Hahn, Andrew W.
    Hale, Peter
    Maughan, Benjamin L.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (01)
  • [46] Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment
    Chen, Yan
    Du, Ella X.
    Sundar, Manasvi
    Betts, Keith A.
    Yin, Xin
    Eiffert, Samantha
    Beauchamp, Karen
    Delgado, Andrew
    Rosenblatt, Lisa
    PHARMACOECONOMICS-OPEN, 2025, 9 (01) : 125 - 136
  • [47] PROGRESSION-FREE SURVIVAL (PFS) MODELING OF FIRST-LINE METASTATIC RENAL CELL CARCINOMA (1L MRCC) USING TUMOR GROWTH INHIBITION (TGI) METRICS.
    Li, J.
    Lin, S.
    Shahin, M.
    Nickens, D.
    Ouellet, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S71 - S71
  • [48] Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects
    Vuorinen, Riikka-Liisa
    Paunu, Niina
    Turpeenniemi-Hujanen, Taina
    Reunamo, Taina
    Jekunen, Antti
    Kataja, Vesa
    Sintonen, Harri
    Purmonen, Timo
    Kellokumpu-Lehtinen, Pirkko-Liisa
    ANTICANCER RESEARCH, 2019, 39 (10) : 5559 - 5564
  • [49] COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE (1L) SYSTEMIC TREATMENTS IN ADVANCED RENAL CELL CARCINOMA (ARCC) IN FRANCE
    Tempelaar, S.
    Kroep, S.
    Marie, L.
    Juban, L.
    Kurt, M.
    Ejzykowicz, F.
    May, J. R.
    Gaudin, A. F.
    Dhanji, N.
    Branchoux, S.
    VALUE IN HEALTH, 2022, 25 (01) : S63 - S63
  • [50] Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.
    Savard, Marie-France
    Wells, J. Connor
    Graham, Jeffrey
    Steinharter, John A.
    McGregor, Bradley Alexander
    Donskov, Frede
    Bjarnason, Georg A.
    Vaishampayan, Ulka N.
    Hansen, Aaron Richard
    Iafolla, Marco Adelmo James
    Zanotti, Giovanni
    Huynh, Lynn
    Duh, Mei Sheng
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345